inhaled insulin

MannKind: Afrezza's slow start due to delays not demand for inhalable insulin
MannKind: Afrezza's slow start due to delays not demand for inhalable insulin
In-Pharma Technologist
MannKind
Afrezza
diabetes
insulin
inhaled insulin
Sanofi
Flag link:
MannKind: Marketing glitches, delays explain slow Afrezza uptake
MannKind: Marketing glitches, delays explain slow Afrezza uptake
BioPharma Dive
MannKind
Sanofi
diabetes
Afrezza
inhaled insulin
Flag link:
Analysts 'skeptical' Sanofi can turn around Afrezza launch, but DTC ads are coming
Analysts 'skeptical' Sanofi can turn around Afrezza launch, but DTC ads are coming
Fierce Pharma
Afrezza
Sanofi
drug launches
inhaled insulin
diabetes
MannKind
Flag link:
Afrezza Users Calling For MannKind To Produce A 2 Unit Cartridge
Afrezza Users Calling For MannKind To Produce A 2 Unit Cartridge
Seeking Alpha
MannKind
diabetes
insulin
Afrezza
inhaled insulin
Flag link:
Afrezza Officially 'Unofficially' Hits $1 Million In Sales
Afrezza Officially 'Unofficially' Hits $1 Million In Sales
Seeking Alpha
Afrezza
diabetes
MannKind
Sanofi
insulin
inhaled insulin
Flag link:
MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
Yahoo
MannKind
Afrezza
inhaled insulin
diabetes
Flag link:
What's Afrezza's Ultimate Potential For MannKind?
What's Afrezza's Ultimate Potential For MannKind?
Yahoo/Benzinga
Afrezza
diabetes
MannKind
inhaled insulin
Flag link:
MannKind: More Confidence, Lower Target
MannKind: More Confidence, Lower Target
Barron's
MannKind
diabetes
inhaled insulin
Flag link:
If You 'Want To Make A Good Drug Great' Cost Must Be Factored In
If You 'Want To Make A Good Drug Great' Cost Must Be Factored In
Forbes
drug pricing
Afrezza
MannKind
Sanofi
inhaled insulin
Flag link:
Afrezza Will Succeed But Initial Sales Likely To Disappoint
Afrezza Will Succeed But Initial Sales Likely To Disappoint
Forbes
Afrezza
diabetes
MannKind
inhaled insulin
Flag link:
No MannKind Buyout Until Afrezza Is Profitable
No MannKind Buyout Until Afrezza Is Profitable
Seeking Alpha
MannKind
M&A
Afrezza
insulin
diabetes
inhaled insulin
Flag link:
What MannKind Investors Can Learn From The Sanofi Conference Call
What MannKind Investors Can Learn From The Sanofi Conference Call
Seeking Alpha
MannKind
Sanofi
Afrezza
diabetes
inhaled insulin
Flag link:
Can Sanofi's kinder, gentler, inhalable Afrezza win reluctant patients over to insulin?
Can Sanofi's kinder, gentler, inhalable Afrezza win reluctant patients over to insulin?
Fierce Pharma Marketing
Sanofi
Afrezza
inhaled insulin
insulin
diabetes
MannKind
Flag link:
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Bidness Etc.
Sanofi
inhaled insulin
Afrezza
diabetes
insulin
drug launches
MannKind
Flag link:
Afrezza Breathes Life Into MannKind
Afrezza Breathes Life Into MannKind
Forbes
Afrezza
MannKind
diabetes
inhaled insulin
Flag link:
The Real News About Afrezza From The JPMorgan Conference
The Real News About Afrezza From The JPMorgan Conference
Seeking Alpha
Afrezza
MannKind
diabetes
inhaled insulin
JPMHC 2015
Flag link:
MannKind Gets Little Love From Sanofi at 'JPM15' Presentation
MannKind Gets Little Love From Sanofi at 'JPM15' Presentation
TheStreet.com
MannKind
diabetes
Sanofi
Afrezza
inhaled insulin
JPMHC 2015
Flag link:
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
Motley Fool
MannKind
Afrezza
inhaled insulin
insulin
diabetes
drug pricing
Flag link:
Can MannKind Corporation Stock Soar in 2015?
Can MannKind Corporation Stock Soar in 2015?
Motley Fool
MannKind
Afrezza
insulin
inhaled insulin
Flag link:
Will Insulin Pricing Be MannKind Corporation's Downfall?
Will Insulin Pricing Be MannKind Corporation's Downfall?
Motley Fool
MannKind
diabetes
insulin
inhaled insulin
Afrezza
drug pricing
Flag link:

Pages